B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

DMPK

MOLECULAR TARGET

DM1 protein kinase

UniProt: Q09013NCBI Gene: 176021 compounds

DMPK (DM1 protein kinase) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting DMPK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gefitinib5.67290
2erlotinib5.55256
3tofacitinib4.65104
4alvocidib4.5291
5ruxolitinib4.2368
6bosutinib4.0858
7bi 25364.0154
8midostaurin3.8546
9canertinib3.5333
10pelitinib3.5032
11tae 6843.4330
12fedratinib3.4029
13at 75193.3327
14jnj 77066213.0921
15lestaurtinib3.0420
16ruboxistaurin2.9418
17kw 24492.6413
18enzastaurin2.087
19rg 5472.087
20Crizotinib0.691
21Dasatinib0.691

About DMPK as a Drug Target

DMPK (DM1 protein kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented DMPK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

DMPK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.